Novartis AG agreed to buy British biotech Myricx Bio for as much as $1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells.
Novartis AG agreed to buy British biotech Myricx Bio for as much as $1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells.
<iframe src="https://statesidedaily.com/embed/cluster/d3168e68173f4c38eea1976beed652e6fd0dd852" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion"></iframe>
